What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?
The T helper cell type 1 (Th1) response is essential to resist leishmaniasis, whereas the Th2 response favors the disease. However, many leishmanial antigens, which stimulate a Th1 immune response during the disease or even after the disease is cured, have been shown to have no protective action. Paradoxically, antigens associated with an early Th2 response have been found to be highly protective if the Th1 response to them is generated before infection. Therefore, finding disease-associated Th2 antigens and inducing a Th1 immune response to them using defined vaccination protocols is an interesting unorthodox alternative approach to the discovery of a leishmania vaccine.
Saved in:
Main Author: | Campos-Neto,A. |
---|---|
Format: | Digital revista |
Language: | English |
Published: |
Associação Brasileira de Divulgação Científica
2005
|
Online Access: | http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0100-879X2005000700001 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Response to Heterologous Leishmanins in Cutaneous Leishmaniasis in Nigeria: Discovery of a New Focus
by: Agwale,Simon M, et al.
Published: (1998) -
Cytotoxic activity in cutaneous leishmaniasis
by: Campos,Taís M, et al.
Published: (2017) -
Mefloquine in the treatment of cutaneous leishmaniasis
by: Correia,Dalmo, et al.
Published: (1999) -
An outbreak of cutaneous leishmaniasis
by: Nishioka,Sérgio de Andrade, et al.
Published: (1988) -
Cutaneous leishmaniasis in Ecuador
by: Cuba-Cuba,César Augusto, et al.
Published: (1996)